The dysregulated AS of the A1β transcript results in a significantly diminished adenosine A1 receptor protein, which is an important therapeutic target in the treatment of MS in peripheral blood mononuclear cells and brain tissue of MS patients (Johnston et al., 2001). This evidence concerns the gene ADORA1 and myeloid sarcoma.